

Instrument, parts and accessories:

NIOX VERO® package AE12-1600 contains: NIOX VERO Instrument, Breathing Handle, Power Supply, USB Cable, Battery, User Manual, USB Memory stick including NIOX® Panel

Accessories:

NIOX VERO Test kit 300 (1 NIOX VERO Sensor 300 + 300 NIOX VERO filters) (12-1830)
 NIOX VERO Test kit 500 (1 NIOX VERO Sensor 500 + 500 NIOX VERO filters) (12-1850)
 NIOX VERO Test kit 1000 (1 NIOX VERO Sensor 1000 + 1000 NIOX VERO filters) (12-1900)

NIOX VERO® Specifications

Exhaled NO – Performance Data	
Measurement range: FeNO	5 to 300 ppb
Exhalation time	10 seconds (preferred mode) 6 seconds (only for children ≤ 10 years who are not able to perform the 10 sec test)
Measurement time	1 min
Accuracy	+/- 5 ppb of measured values ≤50 ppb, max. 10% of measured values > 50 ppb
Precision	<3 ppb of measured value <30 ppb <10% of measured value ≥30 ppb
Instrument memory capacity	15000 measurements
Dimensions (height x width x depth)	145 mm x 185 mm x 41 mm
Weight (including Sensor)	1 kg
Shelf-life (device)	Minimum 5 years at time of delivery, or 15000 measurements

The instrument is verified to fulfill the specified performance under the temperature range within +10 to +35 °C, relative humidity range of 20- 80% and pressure range of 700-1060 hPa.

001469-01 Jul 2015

Aerocrine

NicheMedical
Solutions in Respiratory Care & Diagnosis

Telephone 1300 136 855 Facsimile 1300 664 204
Email: info@nichemedical.com.au
www.nichemedical.com.au

Aerocrine AB P.O. Box 1024, SE-171 21 Solna, Sweden +46 8 629 0781
E-mail : info@aerocrine.com www.niox.com www.aerocrine.com



Learn more about FeNO and how NIOX® is helping to improve and change the way asthma is assessed and managed

www.niox.com

NIOX VERO®

For assessment and management of airway inflammation



NIOX® | CHANGING THE FACE OF ASTHMA CONTROL

NIOX VERO®

NIOX VERO® is a point-of-care device for assessing airway inflammation in patients with respiratory problems such as asthma. NIOX VERO is a further development of NIOX MINO®, the most widely used device for measuring airway inflammation in clinical practice and clinical studies all over the world.

Improved Treatment and Care of Patients

FeNO (Fractional exhaled Nitric Oxide) testing with NIOX VERO offers individualised asthma management that can improve the treatment and care of patients.

Regular FeNO testing of asthma patients with NIOX®, measures allergic airway inflammation (Th2 driven) and helps to:

- Reveal if the patient will benefit from ICS (Inhaled corticosteroids) treatment
- Optimise ICS dose and reduce exacerbations up to 50%^{1,2,3}
- Detect patient non-adherence to ICS⁴

While improving asthma outcomes^{1,2,3} and reducing costs⁵

Expected characteristics for a point-of-care device

- Easy to use
- Quick results
- Reliable and accurate results
- Trouble free maintenance

What NIOX VERO® gives you

Easy to use and quick results

- Designed with patients and health care professionals in mind to ensure best performance
- Can be used both for children and adults (provided patient cooperation)
- Short start-up time
- Quick analysis time, in approximately one minute

Facilitates clinical management decisions at the point of care

Reliable and accurate results

- Internal check of electronics every time at start-up.
- Measurement result obtained only when the patient completes procedure correctly
- Good repeatability allows for one measurement only
- Follows ATS/ERS equipment recommendations
- CE marked

Quality assured measurement results you can rely upon

Trouble free maintenance

- Service and maintenance free device
- 5 years shelf-life and 15 000 measurements
- No calibration required

A product you can rely upon



Use as stand-alone or connected to a PC/tablet (Windows®, but not RT)

NIOX VERO® can be used as stand-alone or connected to a PC. This includes a visual incentive (NIOX® Panel) during the procedure on a PC screen and a program (NIOX Patient) allowing documentation of patient data and capable of use with Electronic Medical Record systems.



Visual incentive on a tablet screen



NIOX® Patient for patient data management

1. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011;378(9795):983-990. 2. Peirsman E, Carvelli T, Hage P, Hanssens L, Pattyn L, Raes M, Sauer K, Vermeulen F, Desager K. Exhaled Nitric Oxide in childhood allergic asthma management a randomised controlled trial. Pediatric Pulmonology, 2013. 3. Syk A, Malinovski A, Johansson G, Udden A, Andreasson A, Lekander M, Alving K. Anti-inflammatory Treatment of Atopic Asthma Guided by Exhaled Nitric Oxide: A Randomized, Controlled Trial. J Allergy Clin Immunol. 2013. 4. Beck-Ripp J, Griese M, Arenz S, Köring C, Pasqualoni B, Bufler P. Changes of exhaled nitric oxide during steroid treatment of childhood asthma. Eur Respir J. 2002;19(6):1015-1019. 5. Lester D, Mohammad A, Leach EE, Hernandez PI, Walker EA. An investigation of asthma care best practices in a community health center. J Health Care Poor Underserved. 2012;23(3 suppl):255-264.